Friedreich Ataxia

• Frataxin deficiency and iron-sulfur cluster defects: FXN mutations cause markedly reduced frataxin protein expression (typically <5-30% of normal levels). Frataxin functions as a critical iron donor and scaffold protein for iron-sulfur (Fe-S) cluster assembly in the mitochondria. Deficiency impairs the activity of multiple Fe-S cluster-containing enzymes including aconitase, complexes I, II, and III of the electron transport chain, and succinate dehydrogenase. This results in compromised oxidative metabolism and impaired mitochondrial ATP production, particularly affecting tissues with high energy demands (dorsal root ganglia, spinal cord, heart, pancreatic beta cells).

• Mitochondrial iron accumulation and oxidative stress: Paradoxically, despite impaired Fe-S cluster synthesis, frataxin deficiency leads to mitochondrial iron accumulation through loss of normal iron export function. Excess mitochondrial iron catalyzes production of reactive oxygen species (ROS) via Fenton chemistry, generating hydroxyl radicals that cause lipid peroxidation, protein oxidation, and DNA damage. The resulting oxidative stress selectively damages neurons with highest metabolic rates—particularly large sensory neurons of the dorsal root ganglia (causing sensory neuronopathy) and Purkinje cells (contributing to ataxia).

• Selective neuronal vulnerability and degeneration: The dorsal root ganglia neurons are the primary site of pathology, with marked loss of large myelinated fibers carrying vibration and proprioceptive sensation. Axonal degeneration (length-dependent from distal to proximal) occurs in spinocerebellar tracts, lateral corticospinal tracts, and peripheral sensory nerves, resulting in the characteristic clinical triad of ataxia, weakness, and sensory loss. Cardiac myocytes undergo hypertrophic changes progressing to restrictive cardiomyopathy due to similar energy depletion and oxidative damage. Pancreatic beta cells are uniquely vulnerable, explaining the high prevalence of diabetes mellitus (up to 20% of patients).

• FXN gene mutations (GAA trinucleotide repeat expansion): >95% of FA cases result from homozygous GAA trinucleotide repeat expansions in intron 1 of the FXN gene. Normal individuals have 5-33 repeats; affected individuals typically have 66-1000+ repeats. Repeat number shows modest correlation with disease severity and age of onset (larger expansions associate with earlier presentation and faster progression). The repeats form stable secondary structures that suppress transcription, resulting in frataxin haploinsufficiency rather than a toxic gain-of-function mechanism.

• Compound heterozygous mutations: Approximately 3-5% of patients harbor compound heterozygous mutations (one allele with GAA expansion, the other with point mutations, small insertions/deletions, or splicing variants). These patients may present with atypical phenotypes, later disease onset, or slower progression depending on the specific allelic combination and residual frataxin activity.

• Genetic background and modifier genes: Significant phenotypic variability exists among patients with identical FXN mutations, implicating genetic modifiers (polymorphisms in GSTT1, SOD2, and other genes involved in antioxidant defense) and environmental factors. Female sex and presence of compound heterozygous mutations are associated with more benign phenotypes and delayed onset.

Cardinal neurological symptoms

• Progressive ataxia (earliest and most prominent symptom): Unsteady gait with truncal instability, dysmetria, dysdiadochokinesia, and nystagmus. Cerebellar signs predominate early; however, ataxia results primarily from sensory loss (sensory ataxia from dorsal root ganglion degeneration) rather than primary cerebellar pathology.
• Lower extremity weakness (develops after ataxia): Distal > proximal pattern reflecting axonal peripheral neuropathy; weakness eventually spreads to upper extremities
• Sensory loss: Distal sensory neuropathy with loss of vibration and proprioception; pain and temperature sensation relatively preserved early
• Dysarthria and dysphonia: Dysarthric speech develops in 95% of patients by advanced stages
• Vision changes: Nystagmus (60%), diplopia, and decreased visual acuity; optic nerve atrophy occurs in advanced disease

Physical examination findings

• Absent or diminished deep tendon reflexes: Typically absent in lower extremities early, later lost in upper extremities
• Extensor plantar responses (Babinski sign): Despite absent reflexes, many patients paradoxically display upgoing toes—a key clinical feature distinguishing FA from other hereditary neuropathies
• Pes cavus and skeletal deformities: High-arched feet with hammer toes; kyphoscoliosis develops in 60-80% of patients due to truncal weakness
• Cardiomegaly and heart failure signs: Tachycardia, irregular pulse (arrhythmias), signs of congestive heart failure in advanced disease

Extraneurological manifestations

• Hypertrophic or restrictive cardiomyopathy (90% of patients): Most common cause of morbidity and mortality; presents with dyspnea, syncope, chest pain, or sudden cardiac death
• Diabetes mellitus or glucose intolerance (20% overt diabetes, 10-20% impaired fasting glucose): Usually non-insulin-dependent initially; presents with polydipsia, polyuria, or incidental hyperglycemia
• Auditory dysfunction: High-frequency hearing loss in 20% of patients
• Scoliosis and spinal deformities: Develop secondary to progressive trunk weakness
• Hypogonadism and sexual dysfunction: Reduced testosterone, infertility

1. 1.Progressive ataxia of gait and limbs (onset typically before age 25)
2. 2.Dysarthria or nystagmus
3. 3.Absent deep tendon reflexes in lower extremities (key feature)
4. 4.Upgoing toe signs (Babinski sign) despite absent reflexes (paradoxical finding)
5. 5.Evidence of axonal sensory neuropathy on electrophysiology
6. 6.No alternative diagnosis on evaluation

• FXN gene analysis: Southern blot or long-range PCR detects GAA repeat expansions; direct sequencing identifies point mutations and small indels
• Repeat number correlates with age of onset: expansions >600 repeats typically cause juvenile-onset disease; smaller expansions (66-300) associated with adult-onset
• Normal individuals: 5-33 repeats; gray zone (34-65 repeats) requires careful interpretation with parental testing
• Expected findings: Homozygous GAA expansions in ~95% of cases; compound heterozygotes or homozygous point mutations in remainder

• Nerve conduction studies: Severely reduced or absent sensory nerve action potentials (SNAPs), particularly in lower extremities; relatively preserved motor conduction velocities with reduced amplitudes
• Electromyography (EMG): Axonal degeneration pattern with fibrillations and positive sharp waves in distal lower extremity muscles
• Pattern: Dorsal root ganglion pathology producing sensory-predominant axonopathy

Cardiac evaluation

• Electrocardiography: Nonspecific ST-T wave changes, left ventricular hypertrophy, T-wave inversions in precordial leads, arrhythmias
• Echocardiography: Concentric or eccentric hypertrophy (systolic dysfunction in advanced disease), normal or preserved ejection fraction early (restrictive physiology), enlarged left atrium
• Cardiac MRI: Reveals characteristic pattern of myocardial iron deposition and fibrosis; prognostic value for sudden cardiac death risk

MRI of brain and spinal cord

• Normal or mildly atrophic spinal cord (spinal cord size typically preserved despite significant neurological deficit—distinguishes FA from other myelopathies)
• Dorsal root atrophy may be visible
• Cerebellar atrophy in advanced disease (not early feature)
• Brain MRI typically normal

Laboratory studies

• Serum glucose and HbA1c: Screen for diabetes mellitus
• Cardiac biomarkers (troponin, BNP/NT-proBNP): Elevated in patients with cardiac involvement; prognostic value
• Serum frataxin levels: Research tool; not routinely measured clinically but reduced in affected individuals

Diagnostic algorithm

1. 1.Clinical suspicion based on progressive ataxia + absent lower extremity reflexes + upgoing toes + sensory neuropathy
2. 2.Nerve conduction studies confirm sensory-predominant axonopathy
3. 3.FXN gene testing provides definitive diagnosis
4. 4.Cardiac screening (ECG, echocardiography) recommended at diagnosis
5. 5.Screen for diabetes mellitus and other endocrinopathies

• ACE inhibitors (e.g., lisinopril) or ARBs (e.g., losartan): First-line agents for hypertrophic cardiomyopathy; slow progression of left ventricular hypertrophy and preserve function. Mechanism: reduces afterload and counteracts neurohormonal activation
• Beta-blockers (e.g., atenolol, propranolol): Reduce heart rate, improve diastolic function, prevent arrhythmias; particularly beneficial in hypertrophic phenotype
• Diuretics (e.g., furosemide): For volume overload and dyspnea in restrictive disease
• Antiarrhythmic agents (e.g., amiodarone): For documented arrhythmias; consider implantable cardioverter-defibrillator (ICD) for secondary prevention of sudden cardiac death or ventricular dysfunction
• Anticoagulation: Warfarin or novel anticoagulants for atrial fibrillation (occurs in advanced disease)
• Regular cardiology surveillance with ECG and echocardiography every 1-2 years; more frequent if ventricular dysfunction present

• Diabetes screening and management: Screen with fasting glucose and HbA1c at diagnosis and regularly thereafter. Manage with dietary modification, metformin, or insulin as needed. Target glucose control similar to non-FA diabetes
• Lipid management: HMG-CoA reductase inhibitors (statins) for dyslipidemia; may have secondary benefits on cardiac remodeling

• Spasticity: Baclofen, tizanidine, or benzodiazepines for lower extremity spasticity
• Pain: Neuropathic pain typically absent or mild; if present, treat with gabapentin, pregabalin, or tricyclic antidepressants
• Tremor: Propranolol or primidone for intention tremor
• Seizures (rare, ~5% of patients): Standard anticonvulsants (levetiracetam preferred due to minimal drug interactions)

• Physical therapy and occupational therapy: Stretching, strength training, balance training; maintain ambulation as long as possible. Evidence suggests structured exercise programs slow functional decline
• Orthotic devices: Ankle-foot orthoses (AFOs) for foot drop and instability; walker or cane for gait support as mobility declines
• Scoliosis management: Spinal fusion considered for severe curves (>50°) causing respiratory compromise or progressive deformity
• Wheelchair accessibility and home modifications: As disease progresses

• Speech therapy: For dysarthria; techniques for rate control and articulation
• Swallowing assessment: Assess for dysphagia as disease progresses; texture modification or feeding tube consideration in advanced stages

• Idebenone: A ubiquinone analog with antioxidant properties; phase 2 trials showed modest improvement in cardiac function, but two large phase 3 trials (MICONOS, IONIA) failed to meet primary endpoints for neurological benefit. Currently prescribed off-label in some countries; not FDA-approved in US
• Antioxidants (vitamin E, coenzyme Q10, N-acetylcysteine): Limited evidence for clinical benefit; often used empirically by patients but not standard of care
• Iron chelators (deferiprone): Target mitochondrial iron accumulation; phase 2/3 trials ongoing; preliminary data suggest potential neurological benefit in some patients
• Gene therapy approaches: Experimental; FAB-101 (in vivo gene therapy) currently in clinical development
• Frataxin replacement strategies: Investigational therapies aimed at restoring frataxin levels

Monitoring and follow-up

• Neurological assessment: Annual clinical evaluation; Friedreich Ataxia Rating Scale (FARS) or Scale for Assessment and Rating of Ataxia (SARA) for quantification
• Cardiac monitoring: ECG and echocardiography annually minimum; more frequent if abnormalities detected
• Metabolic monitoring: Annual glucose screening, lipid panel
• Bone health: Consider DEXA scan and calcium/vitamin D supplementation (increased fracture risk from immobility)
• Ophthalmologic evaluation: At diagnosis and periodically for visual acuity and optic nerve assessment
• Hearing assessment: Baseline and periodic audiometry if symptoms develop

• Sudden cardiac death (most common cause of death in FA patients): Results from severe hypertrophic cardiomyopathy with severe left ventricular obstruction, restrictive physiology, or arrhythmias. Risk stratification by ejection fraction, wall thickness, and QTc prolongation; ICD placement for secondary prevention or selected high-risk patients
• Congestive heart failure: Progressive left ventricular dysfunction (both systolic and diastolic), leading to dyspnea, orthopnea, edema. Manage with standard heart failure medications and devices
• Atrial fibrillation and supraventricular arrhythmias: Occur in advanced disease; anticoagulation required for stroke prevention
• Myocardial ischemia: Anginal symptoms despite angiographically normal coronary arteries (microvascular dysfunction)

Neurological complications

• Severe disability and immobility: Progressive loss of ambulation, typically by third to fourth decade. Secondary complications include pressure ulcers, contractures, deep vein thrombosis
• Aspiration and respiratory failure: Dysphagia and dysarthria progress; aspiration pneumonia risk increases. Feeding tube consideration; respiratory muscle weakness occasionally requires non-invasive ventilation
• Seizures (rare): Occur in ~5% of patients; managed with standard anticonvulsants

Metabolic complications

• Diabetes mellitus and hyperglycemia: Develops in 20% of patients; associated with worse neurological outcomes. Standard diabetes complications including neuropathy, nephropathy, retinopathy possible
• Hypothyroidism and hypogonadism: Screen with TSH and testosterone levels; treat with replacement therapy as needed

Orthopedic complications

• Severe scoliosis (60-80% develop): Thoracic kyphoscoliosis can compromise pulmonary function and cardiac function; surgical fusion considered for curves >50° with progression
• Contractures and joint deformities: Result from chronic immobility and spasticity; prevent with aggressive physical

The stem that gives it away

• **Teenager with staggering gait, pes cavus, hammer toes, and kyphoscoliosis**: onset usually before age 25, autosomal recessive, no sex predilection; overwhelmingly affects people of European, North African, and Middle Eastern ancestry and is rare in sub-Saharan African, Amerindian, and East Asian populations. Frataxin deficiency → impaired Fe-S cluster assembly → mitochondrial iron overload and oxidative injury in the highest-demand tissues.
• Areflexia with an extensor plantar response: the single most tested physical finding. Loss of the reflex arc is peripheral (dorsal root ganglion/large-fiber sensory loss), while the upgoing toe reflects corticospinal tract degeneration — peripheral and central disease in the same patient.
• **GAA trinucleotide repeat in intron 1 of FXN**: a non-coding, loss-of-function (transcriptional silencing) expansion — contrast with the coding CAG expansions of Huntington disease and the autosomal dominant spinocerebellar ataxias.

Best next steps

• Confirm with FXN repeat-sizing genetic testing, not MRI — brain imaging is typically unremarkable early and will not make the diagnosis.
• Get an ECG and echocardiogram at diagnosis, then serial cardiac surveillance; consensus clinical management guidelines for Friedreich ataxia and general ACC/AHA cardiomyopathy principles drive this. Cardiomyopathy, not the ataxia, is the usual cause of death.
• Screen for diabetes with fasting glucose/HbA1c and repeat periodically, per ADA Standards of Care diagnostic thresholds.

Disease-modifying therapy

• Omaveloxolone, an Nrf2 activator, was FDA-approved in 2023 and is the first and currently only approved disease-modifying drug for FA (age ≥16). It slows progression on FARS/mFARS rather than reversing established deficits; transaminase elevation is expected, so LFT monitoring is required. (The OVERVIEW and TREATMENT sections should be reconciled with this.)

The association examiners love

• Ataxia + hypertrophic cardiomyopathy + diabetes in one adolescent is Friedreich ataxia until proven otherwise.

Distractors to avoid

• Ataxia with isolated vitamin E deficiency (AVED): phenotypically near-identical and treatable — check a vitamin E level.
• Ataxia-telangiectasia: earlier onset, oculocutaneous telangiectasias, sinopulmonary infections/IgA deficiency, malignancy risk.
• Subacute combined degeneration (B12): also areflexia plus Babinski, but older patient and potentially reversible with early B12 repletion (recovery may be incomplete if longstanding); macrocytic anemia is often but not always present.
• Charcot-Marie-Tooth: shares pes cavus and areflexia but has no Babinski sign and no cerebellar/ocular findings.
• Do not call the neuropathy demyelinating — absent sensory potentials with preserved motor velocities (axonal sensory neuronopathy).